Skip to main content

Dr. Walid L. Shaib, M.D.

Hematology & Oncology (Hematology & Oncology Physician)

  • Medicare participating

At a glance

Years since graduation
21
In the NPI registry since
2007
Medicare patients seen, 2024
297

The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is

Education and training

  • 2007Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier

Medicare’s Care Compare data doesn’t list this clinician’s medical school. Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).

Specialties and state licenses

  • Hematology & Oncology Physician primary
    GA license 068617

As reported to the NPI registry. To confirm a license is current, check the state medical board.

Map: Hematology & Oncology per capita by county →

Where they work

Hospitals

Medical groups

Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.

Medicare patients and services

Medicare patients, 2024
297
Services billed
1,255
Patients’ average age
75
Most frequent Medicare services, 2023
ServiceTimesPatients
Established patient office or other outpatient visit, 30-39 minutes484215
Established patient office or other outpatient visit, 40-54 minutes21379
Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes14062
Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes5326
New patient office or other outpatient visit, 45-59 minutes4141
Initial hospital care with straightforward or low level of medical decision making, per day, if using time, at least 40 minutes3734
Established patient office or other outpatient visit, 20-29 minutes3529
Initial hospital care with straightforward or low-level medical decision making, if using time, at least 55 minutes3128
New patient office or other outpatient visit, 60-74 minutes2929
Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes1918

Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.

Medicare prescriptions

Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.

Payments from drug and device companies

In 2025, 37 companies reported 227 payments worth $130,346 in total to this clinician.

By type
Compensation for services other than consulting (speaking, faculty)$54,540
Speaking at a medical education program$40,115
Travel and Lodging$16,808
Consulting Fee$14,660
Food and Beverage$4,031
Education$192

What the payments were for

Largest payments other than meals
DateCompanyWhat it was forAmount
Jun 2, 2025Jazz Pharmaceuticals Inc.
Jun 2, 2025
Compensation for services other than consulting (speaking, faculty)
ZIIHERA · HEMATOLOGY/ONCOLOGY
$7,080
Jun 2, 2025Jazz Pharmaceuticals Inc.
Jun 2, 2025
Compensation for services other than consulting (speaking, faculty)
ZIIHERA · HEMATOLOGY/ONCOLOGY
$7,080
Sep 11, 2025Jazz Pharmaceuticals Inc.
Sep 11, 2025
Compensation for services other than consulting (speaking, faculty)
ZIIHERA · HEMATOLOGY/ONCOLOGY
$7,080
Sep 3, 2025Jazz Pharmaceuticals Inc.
Sep 3, 2025
Compensation for services other than consulting (speaking, faculty)
ZIIHERA · HEMATOLOGY/ONCOLOGY
$7,080
Jul 28, 2025AstraZeneca Pharmaceuticals LP
Jul 28, 2025
Compensation for services other than consulting (speaking, faculty)
Company’s descriptionSpeaker Fee
$6,560
May 19, 2025Pfizer Inc.
May 19, 2025
Compensation for services other than consulting (speaking, faculty)
BRAFTOVI · ONCOLOGY
$4,250
Dec 3, 2025Exelixis Inc.
Dec 3, 2025
Speaking at a medical education program
CABOMETYX · Renal Cell Carcinoma (RCC) Hepatocellular Carcinoma (HCC) Differentiated Thyroid
$3,955
Dec 19, 2025Exelixis Inc.
Dec 19, 2025
Speaking at a medical education program
CABOMETYX · Renal Cell Carcinoma (RCC) Hepatocellular Carcinoma (HCC) Differentiated Thyroid
$3,955
Oct 29, 2025Exelixis Inc.
Oct 29, 2025
Speaking at a medical education program
CABOMETYX · Renal Cell Carcinoma (RCC) Hepatocellular Carcinoma (HCC) Differentiated Thyroid
$3,955
Aug 27, 2025Exelixis Inc.
Aug 27, 2025
Speaking at a medical education program
CABOMETYX · Renal Cell Carcinoma (RCC) Hepatocellular Carcinoma (HCC) Differentiated Thyroid
$3,955
All 98 payments other than meals, newest first
All payments other than meals
DateCompanyWhat it was forAmount
Dec 19, 2025Exelixis Inc.
Dec 19, 2025
Speaking at a medical education program
CABOMETYX · Renal Cell Carcinoma (RCC) Hepatocellular Carcinoma (HCC) Differentiated Thyroid
$3,955
Dec 19, 2025Incyte Corporation
Dec 19, 2025
Compensation for services other than consulting (speaking, faculty)
Zynyz · Oncology
$1,370
Dec 15, 2025Exelixis Inc.
Dec 15, 2025
Travel and Lodging
CABOMETYX · Renal Cell Carcinoma (RCC) Hepatocellular Carcinoma (HCC) Differentiated Thyroid · travel to Durham, NC · in-kind
$515
Dec 12, 2025Exelixis Inc.
Dec 12, 2025
Travel and Lodging
CABOMETYX · Renal Cell Carcinoma (RCC) Hepatocellular Carcinoma (HCC) Differentiated Thyroid · travel to Durham, NC · in-kind
$350
Dec 11, 2025Exelixis Inc.
Dec 11, 2025
Travel and Lodging
CABOMETYX · Renal Cell Carcinoma (RCC) Hepatocellular Carcinoma (HCC) Differentiated Thyroid · travel to Durham, NC · in-kind
$70.00
Dec 11, 2025Exelixis Inc.
Dec 11, 2025
Travel and Lodging
CABOMETYX · Renal Cell Carcinoma (RCC) Hepatocellular Carcinoma (HCC) Differentiated Thyroid · travel to Durham, NC · in-kind
$30.00
Dec 3, 2025Exelixis Inc.
Dec 3, 2025
Speaking at a medical education program
CABOMETYX · Renal Cell Carcinoma (RCC) Hepatocellular Carcinoma (HCC) Differentiated Thyroid
$3,955
Dec 3, 2025Exelixis Inc.
Dec 3, 2025
Speaking at a medical education program
CABOMETYX · Renal Cell Carcinoma (RCC) Hepatocellular Carcinoma (HCC) Differentiated Thyroid
$1,695
Nov 24, 2025Exelixis Inc.
Nov 24, 2025
Travel and Lodging
CABOMETYX · Renal Cell Carcinoma (RCC) Hepatocellular Carcinoma (HCC) Differentiated Thyroid · travel to Washington, DC · in-kind
$229
Nov 24, 2025Exelixis Inc.
Nov 24, 2025
Travel and Lodging
CABOMETYX · Renal Cell Carcinoma (RCC) Hepatocellular Carcinoma (HCC) Differentiated Thyroid · travel to Washington, DC · in-kind
$225
Nov 24, 2025Exelixis Inc.
Nov 24, 2025
Travel and Lodging
CABOMETYX · Renal Cell Carcinoma (RCC) Hepatocellular Carcinoma (HCC) Differentiated Thyroid · travel to Washington, DC · in-kind
$225
Nov 21, 2025Exelixis Inc.
Nov 21, 2025
Travel and Lodging
CABOMETYX · Renal Cell Carcinoma (RCC) Hepatocellular Carcinoma (HCC) Differentiated Thyroid · travel to Washington, DC · in-kind
$266
Nov 21, 2025Exelixis Inc.
Nov 21, 2025
Travel and Lodging
CABOMETYX · Renal Cell Carcinoma (RCC) Hepatocellular Carcinoma (HCC) Differentiated Thyroid · travel to Washington, DC
$75.60
Nov 21, 2025Exelixis Inc.
Nov 21, 2025
Travel and Lodging
CABOMETYX · Renal Cell Carcinoma (RCC) Hepatocellular Carcinoma (HCC) Differentiated Thyroid · travel to Washington, DC · in-kind
$70.00
Nov 21, 2025Exelixis Inc.
Nov 21, 2025
Travel and Lodging
CABOMETYX · Renal Cell Carcinoma (RCC) Hepatocellular Carcinoma (HCC) Differentiated Thyroid · travel to Washington, DC
$60.00
Nov 21, 2025Exelixis Inc.
Nov 21, 2025
Travel and Lodging
CABOMETYX · Renal Cell Carcinoma (RCC) Hepatocellular Carcinoma (HCC) Differentiated Thyroid · travel to Washington, DC · in-kind
$30.00
Nov 19, 2025Incyte Corporation
Nov 19, 2025
Compensation for services other than consulting (speaking, faculty)
Zynyz · Oncology
$2,740
Nov 19, 2025Pfizer Inc.
Nov 19, 2025
Consulting Fee
ADCETRIS · ONCOLOGY
$2,310
Nov 19, 2025Exelixis Inc.
Nov 19, 2025
Speaking at a medical education program
CABOMETYX · Renal Cell Carcinoma (RCC) Hepatocellular Carcinoma (HCC) Differentiated Thyroid
$1,695
Nov 19, 2025Exelixis Inc.
Nov 19, 2025
Speaking at a medical education program
CABOMETYX · Renal Cell Carcinoma (RCC) Hepatocellular Carcinoma (HCC) Differentiated Thyroid
$1,695
Nov 10, 2025AstraZeneca Pharmaceuticals LP
Nov 10, 2025
Travel and Lodging
IMFINZI · Oncology · travel to Denver, CO
Company’s descriptionConsulting Expenses
$75.00
Nov 10, 2025AstraZeneca Pharmaceuticals LP
Nov 10, 2025
Travel and Lodging
IMFINZI · Oncology · travel to Denver, CO
Company’s descriptionConsulting Expenses
$60.00
Nov 3, 2025AstraZeneca Pharmaceuticals LP
Nov 3, 2025
Consulting Fee
IMFINZI · Oncology
$3,690
Oct 30, 2025Incyte Corporation
Oct 30, 2025
Travel and Lodging
Zynyz · Oncology · travel to Atlanta, GA
$16.80
Oct 29, 2025Exelixis Inc.
Oct 29, 2025
Speaking at a medical education program
CABOMETYX · Renal Cell Carcinoma (RCC) Hepatocellular Carcinoma (HCC) Differentiated Thyroid
$3,955
Oct 29, 2025Exelixis Inc.
Oct 29, 2025
Speaking at a medical education program
CABOMETYX · Renal Cell Carcinoma (RCC) Hepatocellular Carcinoma (HCC) Differentiated Thyroid
$3,814
Oct 27, 2025Exelixis Inc.
Oct 27, 2025
Travel and Lodging
CABOMETYX · Renal Cell Carcinoma (RCC) Hepatocellular Carcinoma (HCC) Differentiated Thyroid · travel to Austin, TX · in-kind
$230
Oct 27, 2025Exelixis Inc.
Oct 27, 2025
Travel and Lodging
CABOMETYX · Renal Cell Carcinoma (RCC) Hepatocellular Carcinoma (HCC) Differentiated Thyroid · travel to Austin, TX · in-kind
$230
Oct 25, 2025AstraZeneca Pharmaceuticals LP
Oct 25, 2025
Travel and Lodging
IMFINZI · Oncology · travel to Denver, CO · in-kind
Company’s descriptionConsulting Expenses
$323
Oct 24, 2025AstraZeneca Pharmaceuticals LP
Oct 24, 2025
Travel and Lodging
IMFINZI · Oncology · travel to Denver, CO · in-kind
Company’s descriptionConsulting Expenses
$881
Oct 23, 2025Exelixis Inc.
Oct 23, 2025
Travel and Lodging
CABOMETYX · Renal Cell Carcinoma (RCC) Hepatocellular Carcinoma (HCC) Differentiated Thyroid · travel to Austin, TX · in-kind
$395
Oct 23, 2025Exelixis Inc.
Oct 23, 2025
Travel and Lodging
CABOMETYX · Renal Cell Carcinoma (RCC) Hepatocellular Carcinoma (HCC) Differentiated Thyroid · travel to Austin, TX · in-kind
$70.00
Oct 20, 2025Exelixis Inc.
Oct 20, 2025
Travel and Lodging
CABOMETYX · Renal Cell Carcinoma (RCC) Hepatocellular Carcinoma (HCC) Differentiated Thyroid · travel to Garden City, NY · in-kind
$205
Oct 20, 2025Exelixis Inc.
Oct 20, 2025
Travel and Lodging
CABOMETYX · Renal Cell Carcinoma (RCC) Hepatocellular Carcinoma (HCC) Differentiated Thyroid · travel to Garden City, NY · in-kind
$205
Oct 17, 2025Pfizer Inc.
Oct 17, 2025
Compensation for services other than consulting (speaking, faculty)
BRAFTOVI · ONCOLOGY
$3,275
Oct 17, 2025Exelixis Inc.
Oct 17, 2025
Travel and Lodging
CABOMETYX · Renal Cell Carcinoma (RCC) Hepatocellular Carcinoma (HCC) Differentiated Thyroid · travel to Garden City, NY · in-kind
$70.00
Oct 17, 2025Exelixis Inc.
Oct 17, 2025
Travel and Lodging
CABOMETYX · Renal Cell Carcinoma (RCC) Hepatocellular Carcinoma (HCC) Differentiated Thyroid · travel to Austin, TX
$69.93
Oct 17, 2025Exelixis Inc.
Oct 17, 2025
Travel and Lodging
CABOMETYX · Renal Cell Carcinoma (RCC) Hepatocellular Carcinoma (HCC) Differentiated Thyroid · travel to Garden City, NY
$60.00
Oct 17, 2025Exelixis Inc.
Oct 17, 2025
Travel and Lodging
CABOMETYX · Renal Cell Carcinoma (RCC) Hepatocellular Carcinoma (HCC) Differentiated Thyroid · travel to Austin, TX
$51.34
Oct 16, 2025Exelixis Inc.
Oct 16, 2025
Travel and Lodging
CABOMETYX · Renal Cell Carcinoma (RCC) Hepatocellular Carcinoma (HCC) Differentiated Thyroid · travel to Garden City, NY · in-kind
$411
Oct 6, 2025Exelixis Inc.
Oct 6, 2025
Travel and Lodging
CABOMETYX · Renal Cell Carcinoma (RCC) Hepatocellular Carcinoma (HCC) Differentiated Thyroid · travel to Washington, DC · in-kind
$622
Oct 6, 2025Pfizer Inc.
Oct 6, 2025
Education
TUKYSA · ONCOLOGY · in-kind
$16.01
Sep 30, 2025Jazz Pharmaceuticals Inc.
Sep 30, 2025
Travel and Lodging
ZIIHERA · HEMATOLOGY/ONCOLOGY · travel to Newport News, VA · in-kind
$208
Sep 29, 2025Exelixis Inc.
Sep 29, 2025
Travel and Lodging
CABOMETYX · Renal Cell Carcinoma (RCC) Hepatocellular Carcinoma (HCC) Differentiated Thyroid · travel to Durham, NC · in-kind
$497
Sep 26, 2025Alexion Pharmaceuticals, Inc.
Sep 26, 2025
Education
SOLIRIS · Rare Disease · in-kind
Company’s descriptionTextbook
$85.00
Sep 22, 2025Exelixis Inc.
Sep 22, 2025
Travel and Lodging
CABOMETYX · Renal Cell Carcinoma (RCC) Hepatocellular Carcinoma (HCC) Differentiated Thyroid · travel to Austin, TX · in-kind
$542
Sep 11, 2025Jazz Pharmaceuticals Inc.
Sep 11, 2025
Compensation for services other than consulting (speaking, faculty)
ZIIHERA · HEMATOLOGY/ONCOLOGY
$7,080
Sep 3, 2025Jazz Pharmaceuticals Inc.
Sep 3, 2025
Compensation for services other than consulting (speaking, faculty)
ZIIHERA · HEMATOLOGY/ONCOLOGY
$7,080
Sep 3, 2025Jazz Pharmaceuticals Inc.
Sep 3, 2025
Travel and Lodging
ZIIHERA · HEMATOLOGY/ONCOLOGY · travel to Chesapeake, VA · in-kind
$161
Aug 28, 2025Jazz Pharmaceuticals Inc.
Aug 28, 2025
Travel and Lodging
ZIIHERA · HEMATOLOGY/ONCOLOGY · travel to Newport News, VA · in-kind
$232
Aug 27, 2025Exelixis Inc.
Aug 27, 2025
Speaking at a medical education program
CABOMETYX · Renal Cell Carcinoma (RCC) Hepatocellular Carcinoma (HCC) Differentiated Thyroid
$3,955
Aug 21, 2025Incyte Corporation
Aug 21, 2025
Compensation for services other than consulting (speaking, faculty)
Zynyz · Oncology
$628
Aug 21, 2025Exelixis Inc.
Aug 21, 2025
Travel and Lodging
CABOMETYX · Renal Cell Carcinoma (RCC) Hepatocellular Carcinoma (HCC) Differentiated Thyroid · travel to Garden City, NY · in-kind
$607
Aug 20, 2025Janssen Scientific Affairs, LLC
Aug 20, 2025
Consulting Fee$1,320
Aug 20, 2025Jazz Pharmaceuticals Inc.
Aug 20, 2025
Travel and Lodging
ZIIHERA · HEMATOLOGY/ONCOLOGY · travel to Chesapeake, VA · in-kind
$282
Aug 18, 2025Jazz Pharmaceuticals Inc.
Aug 18, 2025
Travel and Lodging
ZIIHERA · HEMATOLOGY/ONCOLOGY · travel to Bloomfield Hills, MI · in-kind
$334
Aug 14, 2025Jazz Pharmaceuticals Inc.
Aug 14, 2025
Travel and Lodging
ZIIHERA · HEMATOLOGY/ONCOLOGY · travel to Newport News, VA · in-kind
$697
Aug 11, 2025Exelixis Inc.
Aug 11, 2025
Travel and Lodging
CABOMETYX · Renal Cell Carcinoma (RCC) Hepatocellular Carcinoma (HCC) Differentiated Thyroid · travel to New York, NY · in-kind
$216
Aug 11, 2025Exelixis Inc.
Aug 11, 2025
Travel and Lodging
CABOMETYX · Renal Cell Carcinoma (RCC) Hepatocellular Carcinoma (HCC) Differentiated Thyroid · travel to New York, NY · in-kind
$205
Aug 10, 2025Exelixis Inc.
Aug 10, 2025
Travel and Lodging
CABOMETYX · Renal Cell Carcinoma (RCC) Hepatocellular Carcinoma (HCC) Differentiated Thyroid · travel to New York, NY · in-kind
$381
Aug 10, 2025Exelixis Inc.
Aug 10, 2025
Travel and Lodging
CABOMETYX · Renal Cell Carcinoma (RCC) Hepatocellular Carcinoma (HCC) Differentiated Thyroid · travel to New York, NY · in-kind
$91.28
Aug 10, 2025Exelixis Inc.
Aug 10, 2025
Travel and Lodging
CABOMETYX · Renal Cell Carcinoma (RCC) Hepatocellular Carcinoma (HCC) Differentiated Thyroid · travel to New York, NY · in-kind
$70.00
Aug 9, 2025Jazz Pharmaceuticals Inc.
Aug 9, 2025
Travel and Lodging
ZIIHERA · HEMATOLOGY/ONCOLOGY · travel to Chesapeake, VA · in-kind
$797
Aug 5, 2025Exelixis Inc.
Aug 5, 2025
Speaking at a medical education program
CABOMETYX · Renal Cell Carcinoma (RCC) Hepatocellular Carcinoma (HCC) Differentiated Thyroid
$3,814
Aug 1, 2025Exelixis Inc.
Aug 1, 2025
Travel and Lodging
CABOMETYX · Renal Cell Carcinoma (RCC) Hepatocellular Carcinoma (HCC) Differentiated Thyroid · travel to Charlotte, NC · in-kind
$459
Aug 1, 2025Exelixis Inc.
Aug 1, 2025
Travel and Lodging
CABOMETYX · Renal Cell Carcinoma (RCC) Hepatocellular Carcinoma (HCC) Differentiated Thyroid · travel to Charlotte, NC · in-kind
$398
Jul 29, 2025AstraZeneca Pharmaceuticals LP
Jul 29, 2025
Compensation for services other than consulting (speaking, faculty)
Company’s descriptionSpeaker Fee
$3,280
Jul 29, 2025Exelixis Inc.
Jul 29, 2025
Speaking at a medical education program
CABOMETYX · Renal Cell Carcinoma (RCC) Hepatocellular Carcinoma (HCC) Differentiated Thyroid
$1,695
Jul 29, 2025Incyte Corporation
Jul 29, 2025
Compensation for services other than consulting (speaking, faculty)
Zynyz · Oncology
$343
Jul 28, 2025AstraZeneca Pharmaceuticals LP
Jul 28, 2025
Compensation for services other than consulting (speaking, faculty)
Company’s descriptionSpeaker Fee
$6,560
Jul 1, 2025Janssen Scientific Affairs, LLC
Jul 1, 2025
Consulting Fee$990
Jul 1, 2025Exelixis Inc.
Jul 1, 2025
Travel and Lodging
CABOMETYX · Renal Cell Carcinoma (RCC) Hepatocellular Carcinoma (HCC) Differentiated Thyroid · travel to New York, NY · in-kind
$521
Jun 25, 2025AstraZeneca Pharmaceuticals LP
Jun 25, 2025
Travel and Lodging
travel to Birmingham, AL · in-kind
Company’s descriptionSpeaker Expenses
$1,196
Jun 11, 2025Exelixis Inc.
Jun 11, 2025
Speaking at a medical education program
CABOMETYX · Renal Cell Carcinoma (RCC) Hepatocellular Carcinoma (HCC) Differentiated Thyroid
$2,825
Jun 3, 2025AstraZeneca Pharmaceuticals LP
Jun 3, 2025
Consulting Fee$2,050
Jun 2, 2025Jazz Pharmaceuticals Inc.
Jun 2, 2025
Compensation for services other than consulting (speaking, faculty)
ZIIHERA · HEMATOLOGY/ONCOLOGY
$7,080
Jun 2, 2025Jazz Pharmaceuticals Inc.
Jun 2, 2025
Compensation for services other than consulting (speaking, faculty)
ZIIHERA · HEMATOLOGY/ONCOLOGY
$7,080
Jun 1, 2025Exelixis Inc.
Jun 1, 2025
Travel and Lodging
CABOMETYX · Renal Cell Carcinoma (RCC) Hepatocellular Carcinoma (HCC) Differentiated Thyroid · travel to Atlanta, GA
$60.20
Jun 1, 2025Exelixis Inc.
Jun 1, 2025
Travel and Lodging
CABOMETYX · Renal Cell Carcinoma (RCC) Hepatocellular Carcinoma (HCC) Differentiated Thyroid · travel to Atlanta, GA
$3.00
May 29, 2025Janssen Biotech, Inc.
May 29, 2025
Education
DARZALEX; TALVEY; TECVAYLI · Oncology · in-kind
$77.99
May 28, 2025Exelixis Inc.
May 28, 2025
Speaking at a medical education program
CABOMETYX · Renal Cell Carcinoma (RCC) Hepatocellular Carcinoma (HCC) Differentiated Thyroid
$1,695
May 27, 2025Pfizer Inc.
May 27, 2025
Travel and Lodging
BRAFTOVI · ONCOLOGY · travel to Albany, GA · in-kind
$1,001
May 24, 2025Jazz Pharmaceuticals Inc.
May 24, 2025
Travel and Lodging
ZIIHERA · HEMATOLOGY/ONCOLOGY · travel to Virginia Beach, VA · in-kind
$105
May 24, 2025Jazz Pharmaceuticals Inc.
May 24, 2025
Travel and Lodging
ZIIHERA · HEMATOLOGY/ONCOLOGY · travel to Bloomfield Hills, MI · in-kind
$105
May 22, 2025Jazz Pharmaceuticals Inc.
May 22, 2025
Travel and Lodging
ZIIHERA · HEMATOLOGY/ONCOLOGY · travel to Virginia Beach, VA · in-kind
$109
May 22, 2025Jazz Pharmaceuticals Inc.
May 22, 2025
Travel and Lodging
ZIIHERA · HEMATOLOGY/ONCOLOGY · travel to Bloomfield Hills, MI · in-kind
$109
May 19, 2025Pfizer Inc.
May 19, 2025
Compensation for services other than consulting (speaking, faculty)
BRAFTOVI · ONCOLOGY
$4,250
May 16, 2025Jazz Pharmaceuticals Inc.
May 16, 2025
Travel and Lodging
ZIIHERA · HEMATOLOGY/ONCOLOGY · travel to Virginia Beach, VA · in-kind
$620
May 16, 2025Jazz Pharmaceuticals Inc.
May 16, 2025
Travel and Lodging
ZIIHERA · HEMATOLOGY/ONCOLOGY · travel to Bloomfield Hills, MI · in-kind
$620
Apr 29, 2025Exelixis Inc.
Apr 29, 2025
Speaking at a medical education program
CABOMETYX · Renal Cell Carcinoma (RCC) Hepatocellular Carcinoma (HCC) Differentiated Thyroid
$1,695
Apr 22, 2025Pfizer Inc.
Apr 22, 2025
Compensation for services other than consulting (speaking, faculty)
BRAFTOVI · ONCOLOGY
$3,275
Apr 2, 2025Cumberland Pharmaceuticals, Inc.
Apr 2, 2025
Compensation for services other than consulting (speaking, faculty)
SANCUSO · ONCOLOGY
$500
Mar 6, 2025Array Biopharma Inc
Mar 6, 2025
Consulting Fee
BRAFTOVI · ONCOLOGY
$700
Feb 27, 2025Exelixis Inc.
Feb 27, 2025
Speaking at a medical education program
CABOMETYX · Renal Cell Carcinoma (RCC) Hepatocellular Carcinoma (HCC) Differentiated Thyroid
$848
Feb 18, 2025Exelixis Inc.
Feb 18, 2025
Speaking at a medical education program
CABOMETYX · Renal Cell Carcinoma (RCC) Hepatocellular Carcinoma (HCC) Differentiated Thyroid
$2,825
Feb 17, 2025Pfizer Inc.
Feb 17, 2025
Education
BRAFTOVI; MEKTOVI · ONCOLOGY · in-kind
$13.04
Feb 5, 2025Exelixis Inc.
Feb 5, 2025
Travel and Lodging
CABOMETYX · Renal Cell Carcinoma (RCC) Hepatocellular Carcinoma (HCC) Differentiated Thyroid · travel to Atlanta, GA
$60.20
Jan 16, 2025E.r. Squibb & Sons, L.l.c.
Jan 16, 2025
Consulting Fee$3,600

Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.

From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.

Who received the most in Connecticut →

Industry-funded research

Named as a principal investigator on 19 industry-funded studies in 2025, from 8 companies. The companies reported $757,252 in research payments for these studies, mostly to the institutions running them.

  • A Phase II Multicenter, Open-label, Single-arm Dose Escalation Study of Asciminib Monotherapy in 2nd Line Chronic Phase - Chronic Myelogenous Leukemia
    Novartis Pharmaceuticals Corporation
  • Randomized, Double-Blind, Multicenter Phase 3 Trial of BMS-986489 (BMS-986012 + nivolumab FDC) in combination with Carboplatin plus Etoposide vs Atezolizumab in combination with Carboplatin plus Etoposide as First-lin…
    E.r. Squibb & Sons, L.l.c.
  • A Multicenter, Open-label, Phase 3 Study to Evaluate the Long-term Safety and Efficacy in Participants who are Currently on Treatment or in Follow-up in Studies That Include Pembrolizumab
    Merck Sharp & Dohme LLC
  • Phase 2/3 BMS-986504+Gemcitabine/Abraxane vs Gemcitabine/Abraxane in Metastatic Pancreatic Ductal Adenocarcinoma (PDAC)
    E.r. Squibb & Sons, L.l.c.
  • A Randomized Open-Label Phase 3 Study of XL092 + Atezolizumab vs Regorafenib in Subjects with Metastatic Colorectal Cancer
    Exelixis Inc.
  • A randomized,phase third study of rilvegostomig in combination with fluoropyrimidine and trastuzumab deruxtecan versus trastuzumab,chemotherapy,and pembrolizumab for the first line treatment of positive gastric cancer
    AstraZeneca Pharmaceuticals LP
  • A Phase III, Randomised, Open-Label, Multicentre Study of Datopotamab Deruxtecan or Docetaxel in Previously Treated TROP2-positive Advanced or Metastatic Non-squamous Non-Small Cell Lung Cancer Without Actionable Geno…
    AstraZeneca Pharmaceuticals LP
  • A Study to Assess Adverse Events and How Intravenously (IV) Infused Telisotuzumab Vedotin (ABBV-399) Moves Through the Body as a Monotherapy in Adult Participants With Previously Treated Non-Squamous Non-Small Cell Lung Cancer (NSCLC)
    AbbVie Inc. · Recruiting · NCT06568939
  • A Multicenter, Double-blind, Randomized Phase 3 Study to Compare the Efficacy and Safety of Belzutifan MK-6482 Plus Pembrolizumab MK-3475 Versus Placebo Plus Pembrolizumab, in the Adjuvant Treatment of Clear Cell Rena…
    Merck Sharp & Dohme LLC
  • Tiragolumab Tecentriq vs Durvalumab in Unresectable Stage III NSCLC
    Genentech, Inc.

From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.

Other Hematology & Oncology clinicians in New Haven

Sources

NPI registry (CMS NPPES, November 2026; record last updated October 29, 2019), Medicare Care Compare, Medicare Physician & Other Practitioners (2024), Medicare Part D Prescribers (2024) and Open Payments (2025). Information is self-reported or billed data and may be out of date; call before visiting.

NPI 1831372481. Official NPI registry record (opens in a new tab). Clinicians can correct their information in NPPES; changes appear here after our next monthly update.